The 6-OHDA (6-hydroxydopamine) rat model is a classic toxin-based model of Parkinson's disease that produces selective destruction of catecholaminergic neurons[@ungerstedt1968]. Unlike the MPTP model, 6-OHDA is administered directly into the brain, producing precise, unilateral lesions that allow each animal to serve as its own control.
History
6-OHDA was first used to model PD in the 1960s by Ungerstedt, who demonstrated that bilateral injections produced a hypokinetic syndrome resembling parkinsonism. The unilateral model was later developed to allow for detailed behavioral and pharmacological studies[@dekundy2007].
Mechanism of Toxicity
flowchart TD
A["6-OHDA Injection"] --> B["Direct Uptake via DAT"]
B --> C["Accumulation in Cytoplasm"]
C --> D["Oxidative Stress"]
D --> E["ROS Generation"]
D --> F["Autooxidation"]
E --> G["DNA Damage"]
E --> H["Protein Oxidation"]
F --> I["Quinone Formation"]
G --> J["Neuronal Death"]
H --> J
I --> J
Key Mechanisms
Selective uptake: 6-OHDA enters catecholaminergic neurons via dopamine and norepinephrine transporters
Oxidative stress: Auto-oxidation generates hydrogen peroxide and quinones
Mitochondrial dysfunction: Inhibits mitochondrial Complex I and IV
DNA damage: Causes oxidative DNA lesions leading to apoptosis
Model Variants
Unilateral Lesions
...
6-OHDA Rat Model of Parkinson's Disease
Overview
The 6-OHDA (6-hydroxydopamine) rat model is a classic toxin-based model of Parkinson's disease that produces selective destruction of catecholaminergic neurons[@ungerstedt1968]. Unlike the MPTP model, 6-OHDA is administered directly into the brain, producing precise, unilateral lesions that allow each animal to serve as its own control.
History
6-OHDA was first used to model PD in the 1960s by Ungerstedt, who demonstrated that bilateral injections produced a hypokinetic syndrome resembling parkinsonism. The unilateral model was later developed to allow for detailed behavioral and pharmacological studies[@dekundy2007].
Mechanism of Toxicity
Mermaid diagram (expand to render)
Key Mechanisms
Selective uptake: 6-OHDA enters catecholaminergic neurons via dopamine and norepinephrine transporters
Oxidative stress: Auto-oxidation generates hydrogen peroxide and quinones
Mitochondrial dysfunction: Inhibits mitochondrial Complex I and IV
DNA damage: Causes oxidative DNA lesions leading to apoptosis
Model Variants
Unilateral Lesions
| Injection Site | Effect | Common Use | |----------------|--------|------------| | Medial forebrain bundle | >95% DA depletion | Rotation behavior | | Substantia nigra | Partial SNc lesion | Selective degeneration | | Striatum | Retrograde degeneration | Progressive model |
Bilateral Lesions
Produces severe hypokinesia
Often lethal due to dysphagia
Used sparingly due to ethical concerns
Key Phenotypes
Motor Symptoms (Unilateral Model)
Circling behavior: Rotation toward lesioned side (spontaneous)
Apomorphine-induced rotation: Rotation toward intact side
Cylinder test: Impaired forelimb use
Stepping test: Deficit in adjustment steps
Non-Motor Symptoms
Olfactory deficits: Early smell dysfunction
Sleep abnormalities: REM sleep changes
Anxiety-like behavior: Increased anxiety in open field
Neurochemical Changes
Dopamine depletion: 90-99% in striatum
TH activity: Severely reduced in SNc
Norepinephrine: Variable depending on injection site
Advantages and Limitations
Advantages
| Advantage | Description | |-----------|-------------| | Precise lesion control | Direct brain injection | | Self-control design | Unilateral model allows within-animal comparison | | Behavioral readouts | Multiple validated behavioral tests | | Drug screening | Rotation test for anti-parkinsonian drugs | | Anatomical precision | Well-defined injection targets |
Limitations
| Limitation | Description | |------------|-------------| | Surgical procedure | Requires stereotaxic surgery | | No Lewy bodies | Lacks protein inclusions | | Acute lesion | Rapid degeneration, not chronic | | Non-physiological | Direct toxin injection is not natural |